Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma.

Published in:

Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-26472-9

By:

• Vos, Joris L.;
• Elbers, Joris B. W.;
• Krijgsman, Oscar;
• Traets, Joleen J. H.;
• Qiao, Xiaohang;
• van der Leun, Anne M.;
• Lubeck, Yoni;
• Seignette, Iris M.;
• Smit, Laura A.;
• Willems, Stefan M.;
• van den Brekel, Michiel W. M.;
• Dirven, Richard;
• Baris Karakullukcu, M.;
• Karssemakers, Luc;
• Klop, W. Martin C.;
• Lohuis, Peter J. F. M.;
• Schreuder, Willem H.;
• Smeele, Ludi E.;
• van der Velden, Lilly-Ann;
• Bing Tan, I.

Publication type:

Article